ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 689,07
0,32%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ocugen Inc (OCGN)

  7. Ocugen Inc (OCGN) Actualités

OCGN

Ocugen (OCGN)

Ocugen Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OCGN
DateHeureSourceTitreSymboleSociété
31/05/202414h36GlobeNewswire Inc.Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic AtrophyNASDAQ:OCGNOcugen Inc
29/05/202413h15GlobeNewswire Inc.Ocugen to Present at BIO International Convention 2024NASDAQ:OCGNOcugen Inc
28/05/202422h05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:OCGNOcugen Inc
28/05/202413h02GlobeNewswire Inc.Ocugen Set to Join Russell 3000® Index Effective June 28, 2024NASDAQ:OCGNOcugen Inc
20/05/202413h00GlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024NASDAQ:OCGNOcugen Inc
17/05/202422h30Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:OCGNOcugen Inc
15/05/202412h30GlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
14/05/202421h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OCGNOcugen Inc
14/05/202414h00GlobeNewswire Inc.Ocugen Provides Business Update with First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
14/05/202413h18IH Market NewsUS Futures Remain Steady Amid Wall Street Caution Ahead of April PPI ReportNASDAQ:OCGNOcugen Inc
14/05/202412h32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OCGNOcugen Inc
10/05/202422h15Edgar (US Regulatory)Form 8-A12G - Registration of securities [Section 12(g)]NASDAQ:OCGNOcugen Inc
10/05/202422h05GlobeNewswire Inc.Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common StockNASDAQ:OCGNOcugen Inc
10/05/202413h45GlobeNewswire Inc.Ocugen to Present at May 2024 Investor ConferencesNASDAQ:OCGNOcugen Inc
03/05/202413h30GlobeNewswire Inc.Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial ResultsNASDAQ:OCGNOcugen Inc
02/05/202413h15GlobeNewswire Inc.Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World CongressNASDAQ:OCGNOcugen Inc
29/04/202412h45GlobeNewswire Inc.Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024NASDAQ:OCGNOcugen Inc
26/04/202415h05GlobeNewswire Inc.UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:OCGNOcugen Inc
26/04/202412h30GlobeNewswire Inc.Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual MeetingNASDAQ:OCGNOcugen Inc
19/04/202413h13GlobeNewswire Inc.Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene TherapyNASDAQ:OCGNOcugen Inc
12/04/202413h30GlobeNewswire Inc.Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital MarketsNASDAQ:OCGNOcugen Inc
10/04/202413h02GlobeNewswire Inc.Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
08/04/202412h30GlobeNewswire Inc.Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa IndicationNASDAQ:OCGNOcugen Inc
05/04/202413h02GlobeNewswire Inc.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic AtrophyNASDAQ:OCGNOcugen Inc
02/04/202414h00GlobeNewswire Inc.Ocugen Provides Business Update with Certain Financials for the Year Ending 2023NASDAQ:OCGNOcugen Inc
02/04/202400h08GlobeNewswire Inc.Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt DiseaseNASDAQ:OCGNOcugen Inc
01/04/202423h43GlobeNewswire Inc.Ocugen to Host Conference Call on Tuesday, April 2 at 8:30 A.M. ET to Provide Business Update with Certain Financials for the Year Ending 2023NASDAQ:OCGNOcugen Inc
18/03/202411h30GlobeNewswire Inc.Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical OfficerNASDAQ:OCGNOcugen Inc
13/03/202413h00GlobeNewswire Inc.Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410NASDAQ:OCGNOcugen Inc
06/03/202413h30GlobeNewswire Inc.Ocugen to Present at Investing in Cures SummitNASDAQ:OCGNOcugen Inc
 Showing the most relevant articles for your search:NASDAQ:OCGN

Dernières Valeurs Consultées

EU
VK
Vallourec
EU
RI
Pernod Ricard
USI
USTECH100
US Tech 100
EU
SGO
Cie de SaintGobain
EU
VIV
Vivendi
EU
GLE
Societe Generale
EU
BN
Danone
NYSE
KO
Coca Cola
NYSE
MCD
McDonalds
COIN
ETHUSD
Ethereum
EU
RNO
Renault
EU
AI
Air Liquide
NYSE
JPM
JP Morgan Chase
EU
PX4
SBF 120
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés